$1.98
2.33% today
NYSE, Apr 01, 06:39 pm CET
ISIN
US5019761049
Symbol
KYTX
Sector
Industry

Kyverna Therapeutics Stock price

$1.93
-0.91 32.04% 1M
-2.96 60.53% 6M
-1.81 48.40% YTD
-20.59 91.43% 1Y
-20.07 91.23% 3Y
-20.07 91.23% 5Y
-20.07 91.23% 10Y
NYSE, Closing price Mon, Mar 31 2025
-0.07 3.50%
ISIN
US5019761049
Symbol
KYTX
Sector
Industry

Key metrics

Market capitalization $83.40m
Enterprise Value $-194.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.67
P/B ratio (TTM) P/B ratio 0.31
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-142.60m
Free Cash Flow (TTM) Free Cash Flow $-116.46m
Cash position $285.98m
EPS (TTM) EPS $-3.46
P/E forward negative
Short interest 8.64%
Show more

Is Kyverna Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Kyverna Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Kyverna Therapeutics forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Kyverna Therapeutics forecast:

Buy
100%

Financial data from Kyverna Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 2.13 2.13
-
-
-2.13 -2.13
-
-
- Selling and Administrative Expenses 28 28
-
-
- Research and Development Expense 110 110
-
-
-140 -140
-
-
- Depreciation and Amortization 2.13 2.13
-
-
EBIT (Operating Income) EBIT -143 -143
-
-
Net Profit -127 -127
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Kyverna Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kyverna Therapeutics Stock News

Neutral
PRNewsWire
5 days ago
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Application (BLA) filing targeted for 2026   Clinical dat...
Positive
Seeking Alpha
11 days ago
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026.
Neutral
PRNewsWire
29 days ago
EMERYVILLE, Calif. , March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025...
More Kyverna Therapeutics News

Company Profile

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Head office United States
CEO Warner Biddle
Employees 112
Founded 2018
Website www.kyvernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today